Daily Ards Research Analysis
Today’s top ARDS-related research spans translational therapeutics, peri-transplant risk management, and ICU vascular access strategy. MSC-derived mitochondrial transplantation restored endothelial barrier function in preclinical ARDS models; VV-ECMO bridging before lung transplant increased bloodstream infections without reducing 1-year survival; and modified midlines offered a safe alternative to PICCs in medical ICUs with distinct complication profiles.
Summary
Today’s top ARDS-related research spans translational therapeutics, peri-transplant risk management, and ICU vascular access strategy. MSC-derived mitochondrial transplantation restored endothelial barrier function in preclinical ARDS models; VV-ECMO bridging before lung transplant increased bloodstream infections without reducing 1-year survival; and modified midlines offered a safe alternative to PICCs in medical ICUs with distinct complication profiles.
Research Themes
- Endothelial-targeted therapeutics in ARDS
- ECMO bridging and post-transplant infection risk
- ICU vascular access optimization for critically ill (including ARDS)
Selected Articles
1. Transplantation of mesenchymal stromal cell-derived mitochondria alleviates endothelial dysfunction in pre-clinical models of acute respiratory distress syndrome.
Human MSC-derived mitochondria were directly transferred to pulmonary microvascular endothelial cells exposed to LPS or ARDS patient plasma, reversing mitochondrial dysfunction and restoring barrier integrity without provoking inflammation. In LPS-challenged mice, intravenous MSC mitochondria reduced lung injury and alveolar inflammatory cell infiltration and increased VE-cadherin mRNA, indicating improved alveolar-capillary barrier function.
Impact: Introduces mitochondrial transplantation as a mechanistically targeted therapy for endothelial dysfunction in ARDS, bridging cellular mechanisms to in vivo efficacy. It provides a plausible route to phenotype-driven interventions in a high-mortality syndrome.
Clinical Implications: Supports development of mitochondrial transplantation as an adjunctive therapy for ARDS, particularly for restoring endothelial barrier function. Patient selection by inflammatory phenotype, dosing, delivery route, and safety need evaluation before clinical translation.
Key Findings
- LPS or ARDS patient plasma induced mitochondrial dysfunction and hyperpermeability in HPMEC.
- MSC-derived mitochondria were internalized by HPMEC without cytotoxic or pro-inflammatory effects, restoring mitochondrial function and barrier integrity at 24 h.
- In LPS-challenged mice, intravenous MSC mitochondria reduced lung injury and alveolar inflammatory cell infiltration and increased lung VE-cadherin mRNA.
Methodological Strengths
- Translational design integrating primary human endothelial cells with in vivo mouse validation.
- Testing against ARDS patient plasma stratified by inflammatory phenotypes and multiple functional readouts (barrier, mitochondrial function, VE-cadherin).
Limitations
- Preclinical models without long-term safety, biodistribution, or dosing optimization data.
- Mechanistic pathways of mitochondrial uptake and integration were not deeply dissected.
Future Directions: Conduct large-animal studies and first-in-human feasibility trials; define dosing, delivery routes, and patient phenotypes most likely to benefit; elucidate uptake mechanisms and compare with MSCs/extracellular vesicles.
BACKGROUND: Pulmonary endothelial dysfunction with increased capillary permeability is a key aspect in the pathogenesis of acute respiratory distress syndrome (ARDS). It has been demonstrated that mesenchymal stromal cells (MSC) can modulate host cells through mitochondrial transfer. Although mitochondrial transplantation is a promising treatment strategy for conditions underpinned by mitochondrial dysfunction, its therapeutic potential in ARDS has not been sufficiently investigated. Herein, we tested the potential of MSC mitochondrial transplantation to restore functionality of the pulmonary endothelium in pre-clinical models of ARDS. METHODS: Mitochondria (mt) derived from human bone-marrow MSC were isolated and immediately used for transplantation to primary human pulmonary microvascular endothelial cells (HPMEC) in the presence of Escherichia coli lipopolysaccharide (LPS) or plasma samples from ARDS patients classified into hypo- and hyper-inflammatory phenotypes. Mitochondrial function, inflammatory status, and barrier integrity of HPMEC were assessed at 24 h. LPS- challenged mice were treated with MSC-mt intravenously, and the severity of lung injury and inflammatory response were evaluated. RESULTS: Exposure to LPS or ARDS plasma induced endothelial hyperpermeability associated with mitochondrial dysfunction. MSC-mt were readily internalized by HPMEC without cytotoxicity or inflammatory response, mitigating mitochondrial dysfunction and restoring barrier integrity. In vivo, administration of MSC-mt alleviated lung injury, reduced inflammatory cell infiltration in the alveoli and increased VE-cadherin mRNA levels in the lung tissue, indicating restoration of the alveolar-capillary barrier integrity. CONCLUSION: This study demonstrated MSC mitochondrial transplantation as a promising therapeutic approach for treatment of endothelial dysfunction in the context of acute inflammation. Further exploration of mitochondrial transplantation in ARDS is warranted.
2. Impact of pre-transplant veno-venous extracorporeal membrane oxygenation on post-lung transplant infections.
In a single-center retrospective cohort of 293 lung transplants, pre-transplant VV-ECMO was associated with a higher and earlier rate of bacterial bloodstream infections (HR 2.36) but not with increased respiratory infections or reduced one-year survival. These findings support continued VV-ECMO bridging while highlighting a need for targeted post-transplant infection prevention.
Impact: Defines infection risk profiles associated with VV-ECMO bridging, separating bloodstream from respiratory infection effects without compromising survival—actionable for peri-transplant management.
Clinical Implications: Maintain VV-ECMO as a bridge to transplant but implement intensified surveillance and prophylaxis for bloodstream infections, especially within the first 3–4 months; tailor antimicrobial strategies and central line protocols.
Key Findings
- Pre-transplant VV-ECMO independently predicted bacterial bloodstream infection (HR 2.36, 95% CI 1.00–5.53; p=0.049).
- Respiratory infection incidence was similar, but time to first respiratory infection was shorter with VV-ECMO (8 vs 63 days).
- One-year survival did not differ between VV-ECMO and non-ECMO groups (81.1% vs 89.8%; p=0.16).
Methodological Strengths
- Comparative cohort with multivariable Cox modeling to adjust for confounders.
- Clinically meaningful endpoints including infection timing and 1-year survival.
Limitations
- Single-center retrospective design with potential selection and residual confounding.
- Small VV-ECMO subgroup (n=37) limits precision; pathogen and device-related details may be underreported.
Future Directions: Prospective multicenter validation with standardized infection surveillance; evaluate catheter protocols, antimicrobial stewardship, and microbiome/colonization markers; assess impact on chronic allograft dysfunction.
Bridging critically ill patients to lung transplantation with veno-venous extracorporeal membrane oxygenation (VV-ECMO) may increase infection risk, yet its impact on post-transplant outcomes remains unclear. We evaluated the incidence, timing, and risk factors for respiratory and bloodstream infections in patients supported with pre-operative VV-ECMO and assessed one-year survival. We conducted a retrospective cohort study of 293 adult lung transplant recipients at a single center between January 2018 and June 2023. Thirty-seven patients received pre-transplant VV-ECMO, and 256 did not. We compared the incidence and median time to first respiratory and bloodstream infections and estimated one-year survival. Cox proportional hazard models identified independent predictors of infection. VV-ECMO patients were younger (median 53.0 vs 63.0 years) and more often underwent bilateral transplantation for acute respiratory distress syndrome. Respiratory infections occurred in 64.9% of the VV-ECMO group versus 56.6% of controls (p = 0.38), with a shorter median time to first respiratory infection (8 vs 63 days). Bacterial bloodstream infections were more frequent after VV-ECMO (18.9% vs 6.3%, p = 0.016) and occurred earlier (99 vs 162 days). In multivariate analysis, VV-ECMO independently predicted bloodstream infection (HR 2.36, 95% CI 1.00-5.53; p = 0.049) but not a respiratory infection. One-year survival was equivalent (81.1% vs 89.8%; p = 0.16). Pre-transplant VV-ECMO is associated with earlier and increased bloodstream infections but does not compromise one-year survival, supporting its continued use as a bridge to lung transplantation.
3. Comparison of modified midlines versus PICCs in a medical ICU setting: A retrospective study.
In 142 medical ICU patients, modified midlines were preferentially used in ARDS, COPD, CVD, and COVID-19 and for vasoactive infusions. Compared with PICCs, modified midlines had lower unplanned removal and puncture-site infection but higher puncture-site bleeding; indwelling duration ≥12 days was the sole independent risk factor for overall complications.
Impact: Provides comparative safety and utilization data for medium-term vascular access in ICU populations, informing device selection in patients with ARDS and other critical illnesses.
Clinical Implications: For non-chemotherapy ICU patients requiring medium-term access, consider modified midlines to reduce unplanned removal and puncture-site infection; limit dwell time to <12 days when feasible and monitor bleeding risk in older patients or prolonged ICU stays.
Key Findings
- Modified midlines were used more often than PICCs in patients with ARDS, COPD, cardiovascular disease, and COVID-19, and more for vasoactive drugs than chemotherapy.
- Compared with PICCs, modified midlines had lower rates of partial/complete catheter removal and puncture-site infection but higher puncture-site bleeding.
- Indwelling duration ≥12 days independently predicted overall complications; age ≥60 years and ICU stay ≥14 days predicted puncture-site bleeding.
Methodological Strengths
- Direct device-to-device comparison in a real-world medical ICU cohort.
- Stratified and multivariate analyses to identify independent risk factors.
Limitations
- Retrospective single-center design with potential confounding by indication and selection bias.
- No randomization; limited generalizability and incomplete capture of long-term complications.
Future Directions: Prospective randomized comparisons of modified midlines versus PICCs in ICU patients, including thrombosis and CLABSI outcomes, and cost-effectiveness analyses.
Intensive care units (ICUs) frequently host patients who often need to be infused with all kinds of drugs. Currently, modified midlines and peripherally inserted central catheters (PICCs) are used frequently. The present retrospective research aims to assess the use, efficacy, and complications due to modified midlines and PICCs in the treatment of patients in a medical ICU. One hundred forty-two patients hospitalized were inserted with a modified midline or PICC. The choice of catheters for different underlying diseases, actual clinical application, the number of days of dwell time, and complications were compared. Risk factors for complications and puncture-site bleeding were investigated. Compared to PICCs, modified midlines were used far more frequently in patients suffering from acute respiratory distress syndrome, chronic obstructive pulmonary disease, cardiovascular diseases, and coronavirus-19 infections; however, this is not the case in malignancy patients. Moreover, modified midlines were more frequently used for the infusion of vasoactive drugs rather than chemotherapeutic drugs. As for overall complications associated with catheter placement, it was significantly different between the 2 groups. Stratified analysis revealed that in the modified midline group, the incidence of partial or complete catheter removal and puncture-site infection was less than the incidence among PICC group; however, modified midline group developed puncture-site bleeding more frequently than PICC group. Multivariate analyses indicated that a catheter indwelling duration of ≥12 days was the only risk factor for complications, rather than PICC. Meanwhile, it also showed that the 2 risk factors for puncture-site bleeding were an age of ≥60 years and ICU stay ≥14 days. In the medical ICU, modified midlines offer a safe alternative to PICCs for medium-term access in non-chemotherapy patients, reducing rates of unplanned removal and puncture-site infection while simplifying clinical workflow.